Cancer Research Technology has sealed a deal with MSD to develop new treatments targeting blood disorders and cancer.
News
US breakthrough status for AstraZeneca, AbbVie drugs
AstraZeneca’s Lynparza has picked up a breakthrough designation in the US as a monotherapy for certain forms of prostate cancer.
US priority review for Merck’s C. difficile antitoxin
US regulators have agreed to review an experimental antitoxin being developed by Merck & Co to prevent recurrence of the superbug Clostridium difficile.
Novartis unveils Alcon revamp as sales decline
Novartis has announced plans to re-organise its eye unit Alcon in order to secure future growth and lift the company’s profit.
Johnson & Johnson 2015 sales miss the mark
Johnson & Johnson has reported Q4 and full year financial results for 2015 slightly below expectations.
NHS cancer patients gain access to four new therapies
The National Institute for Health and Care Excellence has issued final recommendations endorsing National Health Service use of new therapies for ovarian cancer, multiple myeloma and prostate cancer, but rejecting one for gastric cancer.
NICE final OK for Boehringer’s lung drug Ofev
Cost regulators have approved the routine use of Boehringer Ingelheim’s Ofev as a treatment for some patients with the lung-scarring disease idiopathic pulmonary fibrosis on the NHS in England and Wales.
Galapagos pulls plug on ulcerative colitis drug
Galapagos has pulled the plug on its investigational ulcerative colitis drug GLPG1205 after it failed to hit targets in a mid-stage trial.
E-cigs are toxic immune suppressants, mice study finds
The debate over the safety of e-cigarettes has taken another turn after US researchers found evidence to suggest that they are toxic to human airway cells, suppress immune defences and alter inflammation, while also boosting bacterial virulence.
NICE recommends seven drugs for rheumatoid arthritis
Cost regulators for the NHS in England and Wales have issued final guidelines recommending seven biological disease modifying drugs for severe rheumatoid arthritis which has not responded to conventional disease modifying therapy.
Charity calls for tobacco industry to ‘cough up’ for smokers
Cancer Research UK has kicked off a new campaign calling on the government to make the tobacco industry pay out for the health damage caused by its products and help reduce the number associated deaths.
NHS ranks 14th in survey of EU health systems
The NHS has ranked 14th in a new survey of health systems in Europe, with the report accusing the health service of delivering mediocre results in several areas.
US review for Amgen’s Humira biosimilar
US regulators have agreed to review Amgen’s ABP 501, a biosimilar version of AbbVie’s anti-inflammatory super-blockbuster Humira, with a decision on the drug’s filing expected by September 25 this year.
Merck, Affimed to test Hodgkin lymphoma combo
Merck & Co has signed a clinical trials pact with German biopharma Affimed that will test a combination of two immunotherapies for Hodgkin lymphoma.
US ‘orphan status’ for Immunocore’s eye cancer drug
The US Food and Drug Administration has granted Immunocore’s IMCgp100 orphan drug designation for the treatment of uveal melanoma.
